Hamostaseologie 2025; 45(S 01): S39
DOI: 10.1055/s-0044-1801603
Abstracts
Topics
T-06 Diagnostics and laboratory tests

Comparison of light transmission aggregometry in patients with bleeding of unknown cause and healthy blood donors

M Metze
1   University of Leipzig Medical Center, Department of Cardiology, Leipzig, Germany
,
L-T Hülsken
2   University of Leipzig Medical Center, Division of Hemostaseology, Leipzig, Germany
,
M Federbusch
3   University of Leipzig Medical Center, Institute of Laboratory Medicine, Leipzig, Germany
,
M Weise
2   University of Leipzig Medical Center, Division of Hemostaseology, Leipzig, Germany
,
R Siegemund
4   University of Leipzig Medical Center, Medical ICU, Leipzig, Germany
,
A Siegemund
2   University of Leipzig Medical Center, Division of Hemostaseology, Leipzig, Germany
4   University of Leipzig Medical Center, Medical ICU, Leipzig, Germany
,
R Henschler
5   University of Leipzig Medical Center, Institute of Transfusion Medicine, Leipzig, Germany
,
S Petros
2   University of Leipzig Medical Center, Division of Hemostaseology, Leipzig, Germany
4   University of Leipzig Medical Center, Medical ICU, Leipzig, Germany
,
C Pfrepper
2   University of Leipzig Medical Center, Division of Hemostaseology, Leipzig, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 
 

    Introduction: Light transmission aggregometry (LTA) plays an important role in the detection and characterization of platelet function disorders in patients with a positive bleeding history. However, the optimal concentration of agonists remains unclear. This study aimed to evaluate different agonist concentrations for the detection of patients with bleeding of unknown cause (BUC) and in healthy blood donors.

    Method: We retrospectively evaluated the results of LTA performed between 2017 and 2019 in patients with BUC at the University Hospital Leipzig, Germany and compared those with prospectively collected LTA measurements from healthy blood donors. LTA was measured on a PAP-8 analyser after induction with 2µM, 5µM and 20µM ADP in both groups. In addition, 1.0mM arachidonic acid (AA) and 5µM epinephrine were used in BUC, and in healthy blood donors 1.0mM, 1.5mM AA and 5µM and 10µM epinephrine. The prediction of the ISTH-BAT score for abnormal LTA was assessed.

    Results: After induction with 2µM ADP, 43.8% of the patients with BUC and 24.3% of the healthy blood donors had abnormal maximum aggregation (MA), which reduced to 5.8% and 4.6% after induction with 5µM ADP, respectively. Patients with BUC had a higher proportion of abnormal MA after induction with 1mM AA (18.5%) compared to healthy donors (3.6%). No significant difference was observed after epinephrine induction. There was a high fluctuation of LTA in patients with multiple measurements. The sensitivity of an abnormal ISTH-BAT score to predict an abnormal LTA was<22% and the NPV>70%.

    Conclusion: This study reveals a high proportion of abnormal LTA results in patients with BUC and healthy blood donors after induction with low concentrations of ADP and AA. The recommendations for low concentrations in guidelines for platelet function testing should be re-evaluated.


     

    Conflict of Interest:

    C.P. reports institutional grants for research and studies from Chugai/Roche, Takeda, Zacros, and LEO Pharma and honoraria for lectures or consultancy from Bayer, BioMarin, Chugai/Roche, CSL Behring, Novo Nordisk, Pfizer, BMS, Sobi, and Takeda.

    Publikationsverlauf

    Artikel online veröffentlicht:
    13. Februar 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany